Labor Dr. Wisplinghoff and Genomic Testing Cooperative (GTC) Partner To Deploy GTC Comprehensive Suite of Tissue and Liquid Biopsy Testing

Labor Dr. Wisplinghoff, and Genomic Testing Cooperative (GTC), are excited to announce the launch of their collaboration. With the innovative Next Generation Sequencing (NGS) DNA/RNA tests from GTC, Labor Dr. Wisplinghoff expands its broad analytical spectrum in pathology and hematology and  provides physicians in Germany with deeper molecular insights for more precise diagnosis and therapy monitoring of solid tumors and hematologic neoplasms. Labor Dr. Wisplinghoff will, with support from GTC, utilize the proven GTC portfolio of tissue and liquid biopsy testing for hematologic neoplasms and solid tumors. Particularly, comprehensive RNA analysis represents a significant advance in clinical utility for the diagnosis and care of cancer patients. Through expanded and deeper molecular analyses, physicians receive the best possible foundation for developing optimized precision treatment plans and improving therapy outcomes.

As a member of the GTC cooperative (Co-Op) group, Labor Dr Wisplinghoff will gain access to leading edge group proprietary capabilities and datasets and the opportunity to participate in coordinated global research and development and associated clinical trial programs, and so accelerate and enhance its contribution to the development of precision medicine in the German healthcare landscape. Having Labor Dr Wisplinghoff join the Co-Op will strengthen the scientific and medical experience within the group, continue the extension of its geographic reach, and deepen and widen its patient access footprint.

Professor Hilmar Wisplinghoff, Managing Partner at Labor Dr. Wisplinghoff, stated "We are excited to partner with GTC and to bring cutting-edge advances in genomics and precision medicine into the German healthcare space. We believe that together we can be at the forefront of developing and deploying products and services that offer ‘step change’ patient outcomes in the treatment of cancers in Germany."       

Dr. Maher Albitar, Founder, CEO and Chief Medical Officer at GTC, added "We are very thrilled to partner with Labor Dr. Wisplinghoff in adapting and bringing to Germany our proven and comprehensive portfolio of tissue and liquid biopsy tests for Hematologic Neoplasms and Solid Tumors.  Both our companies are focused on innovation and serving patients, and through our partnership we aim to be instrumental in driving the democratization of genomic testing in Germany and making it available and affordable to every patient with cancer."